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Abstract
Pneumocystis jiroveci pneumonia (PJP) is associated with high morbidity and mortality after 
hematopoietic stem cell transplantation (HSCT). Little is known about PJP infections after HSCT 
because of the rarity of disease given routine prophylaxis. We report the results of a CIBMTR 
study evaluating the incidence, timing, prophylaxis agents, risk factors, and mortality of PJP after 
autologous (auto) and allogeneic (allo) HSCT. Between 1995 and 2005, 0.63% allo recipients and 
0.28% auto recipients of first HSCT developed PJP. Cases occurred as early as 30 days to beyond 
a year after allo HSCT. A nested case cohort analysis with supplemental data (n=68 allo cases, 
n=111 allo controls) revealed that risk factors for PJP infection included lymphopenia and 
mismatch after HSCT. After allo or auto HSCT, overall survival was significantly poorer among 
cases vs. controls (p=0.0004). After controlling for significant variables, proportional hazards 
model revealed that PJP cases were 6.87 times more likely to die vs. matched controls (p<0.0001). 
We conclude PJP infection is rare after HSCT but is associated with high mortality. Factors 
associated with GVHD and with poor immune reconstitution are among the risk factors for PJP 
and suggest that protracted prophylaxis for PJP in high-risk HSCT recipients may improve 
outcomes.
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Introduction
Pneumocystis jiroveci (formerly Pneumocystis carinii) pneumonia (PJP), a unicellular 
fungal infection, is a severe infectious complication in immunocompromised hosts, 
including hematopoietic stem cell transplant (HSCT) recipients, often leading to fulminant 
respiratory failure.1–3 In immunocompromised hosts, PJP disease confers increased 
mortality, with published historical rates as high as 34–62%4–7, although data in the current 
era are unknown due to the rarity of disease with the implementation of routine PJP 
prophylaxis. Prior to prophylaxis, PJP disease was reported in 5–37% of HSCT patients8, 9. 
However, since the advent of PJP prophylaxis, this incidence has decreased, with recent 
reports suggesting 1–6%4, 7, 9–13 and a few reports of no cases in as many as 120 high-risk 
HSCT recipients14. However, with this rarity of disease, the actual incidence of PJP after 
HSCT remains unknown, as the largest number of PJP cases in reports is often under 10, 
suggesting that these data may overestimate the true incidence due to reporting bias, since 
cohort studies are often undertaken in the setting of outbreaks.15–17
Multiple studies have suggested that trimethoprim/sulfamethoxazole (TMP/SMX) is the 
drug of choice to prevent PJP in immunocompromised patients due to its efficacy against 
PJP and concurrent prophylaxis against other opportunistic pathogens including Toxoplasma 
gondii, Nocardia, and susceptible bacteria (e.g. Staphylococcus, Streptococcus 
pneumoniae)1, 5, 8, 10, 18. However, it is not well tolerated in HSCT recipients, with reported 
intolerance as high as 55% requiring discontinuation of the drug due to rash, marrow 
suppression, and allergy19–23. For these TMP/SMX intolerant patients, PJP prophylaxis 
alternative agents include: aerosolized or intravenous pentamidine, dapsone, atovaquone, 
clindamycin and pyrimethamine, though clindamycin and pyrimethamine have been largely 
abandoned due to lack of efficacy.20, 22–25 However, there is no consensus regarding efficacy 
of these agents in HSCT patients, nor an appropriate algorithm for choosing among these 
second line agents. PJP breakthrough rates are as high as 9% for aerosolized pentamidine, 
7.2% for dapsone, and not well categorized for intravenous pentamidine and atovaquone, 
with several anecdotal reports of failures with these agents, although these account for less 
than 300 total reported patients26–30. As a result of these sparse data, the most recent 
recommendation from the Cochrane Collaboration includes only TMP/SMX and suggests 
continuation for at least 6 months after HSCT and continuation until discontinuation of 
immune suppression. 10, 31
PJP disease risk and clearance relies upon recovery of lymphocyte numbers and function. 
Not surprisingly, published factors linked to PJP infection after HSCT are those associated 
with lymphocyte impairment, including: steroids, T cell depletion in vitro or in vivo, 
persistent lymphopenia, immunosuppression, graft vs. host disease (GVHD), and 
relapse.4, 11, 32–35. The highest period of risk for PJP is thought to be from day 80 through 
day 270 post HSCT due to impaired lymphocyte function during this timeframe, though very 
early and very late cases have been described.4, 18, 36–39 While these risk factors are likely 
determinants of PJP disease, there are conflicting reports, and small sample size limits 
interpretation.
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Since PJP is an uncommon event in the HSCT population, the incidence, timing, risk factors, 
and best prophylaxis regimens may only be addressed in a large registry study, which 
overcomes the limitation of disease rarity. The reported high mortality underscores the need 
for these data, to both determine the true mortality in a sufficiently large cohort, and reveal 
the population most at risk, for whom new interventions could be targeted. Thus, we 
interrogated the largest HSCT database, the Center for International Blood and Marrow 
Transplant Research (CIBMTR) registry, to identify the incidence of PJP, and then 
performed a nested case control study to assess risk factors and PJP-associated mortality, 
and to provide evidence-based data for choice of prophylaxis agents for HSCT recipients.
Methods
Data Source
The CIBMTR is a voluntary working group of more than 450 transplantation centers 
worldwide that contribute detailed data on consecutive HSCTs to a Statistical Center located 
at the Medical College of Wisconsin in Milwaukee and the National Marrow Donor Program 
(NMDP) Coordinating Center in Minneapolis. Participating centers are required to report all 
transplantations consecutively; compliance is monitored by onsite audits. The CIMBTR 
maintains an extensive database of detailed patient-, transplant-, and disease-related 
information, and prospectively collects data longitudinally with yearly follow-ups. 
Observational studies conducted by the CIBMTR are performed in compliance with HIPAA 
regulations as a public health authority and also in compliance with all applicable federal 
regulations pertaining to the protection of human research participants, as determined by a 
continuous review by the Institutional Review Boards of NMDP and the Medical College of 
Wisconsin.
Patients
This study includes all patients, irrespective of age, who received HSCT for either malignant 
or non-malignant indications between 1995 and 2005 and identified with PJP infection 
within 2 years of transplantation. PJP infection was captured in the CIBMTR data forms 
either as an infection documented in the post-transplant period or listed as a primary or 
secondary cause of death. Centers report based upon organism identification and those cases 
reported as suspected fungal infection were excluded. Those with a history of PJP infection 
prior to HSCT were excluded. A subsequent analysis was performed to interrogate incidence 
only using the same inclusion and exclusion criteria from 2006–2012.
Analysis
This is a nested case control cohort study to assess for clinical factors impacting 
development of PJP and outcomes. Controls were selected 3:1 based on 1) type of transplant 
(autologous or allogeneic), 2) the same duration of post-HSCT follow-up (ensuring controls 
are alive at time of case PJP diagnosis), and 3) the same disease indication for HSCT. A 
marginal proportional hazards model for clustered data was used for matching 40. 
Supplemental data forms were requested to evaluate PJP prophylaxis agents, concomitant 
neutrophil and lymphocyte counts, and methods of PJP diagnosis including autopsy, 
bronchoalveolar lavage, and methenamine silver. Beta-D glucan was not included as a 
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diagnostic modality due to the study period evaluated. We received supplemental data on 97 
cases (57%) and 236 controls (47%). Data forms were missing PJP prophylaxis data for 14 
cases (14%) and 21 controls (9%), and the time of administration of prophylaxis was 
reported as unknown for 28 cases (29%) and 45 controls (19%). Therefore, detailed 
prophylaxis medication within the 30 days prior to the diagnosis of PJP was only available 
for 33% of cases and 34% of controls (Figure 1). Consequently, information on PJP 
prophylaxis is described but was unable to be analyzed as a risk factor for PJP.
The effect of PJP infection on overall survival of the entire study population was assessed 
using a proportional hazards model adjusting for the effect of other significant covariates 
including time dependent variables of PJP infection (main effect variable) and GVHD, 
GVHD was incorporated as a variable in the multivariable model, such that the GVHD event 
must have occurred prior to the PJP infection to be evaluable. This precludes studying 
GVHD as an outcome. Interactions between PJP infection and significant covariates were 
tested. Backward elimination was used to select significant covariates. Analysis was 
performed using SAS 9.2.
Results
Incidence and timing of PJP infection after HSCT
Between 1995 and 2005, the incidence of PJP was 0.63% in allogeneic recipients (n=177 
cases of 27,934 total) and 0.28% in autologous recipients (n=52 cases of 18,525 total). This 
has not changed with time as the incidence was 0.53% in allo-recipients and 0.32% in auto-
recipients from 2006 – 2012. PJP developed both early (between day 0 – 60) and late 
(beyond day 270) after allo-HSCT. PJP occurred at a median of 120 days (range, 2 – 620 
days), with 26% of cases occurring early (median 31, range 5–56 days), 50% occurring 
between 60 and 270 days after HSCT (median 120, range 60–265 days), and 24% occurring 
late (median 342, range 279–587 days) (Figure 2). After auto HSCT, although the numbers 
were small, a similar trend was observed with 18% prior to day 60, 55% between day 60 and 
270, and 27% after day 270. Of those that completed the secondary forms, bronchoalveolar 
lavage was the most common method of diagnosis for allogeneic and autologous recipients, 
for allogeneic recipients, this totaled 74%, though autopsy (2%), biopsy (4%), sputum (9%), 
imaging (9%), and methanamine silver (2%) were also reported.
Risk factors for PJP infection after HSCT
Cases and controls were similar in terms of gender, age, Karnofsky score, co-existing 
endocrine or pulmonary diseases, disease status at the time of transplant, and prior 
autologous HSCT for both autologous and allogeneic recipients (Table 1). For allogeneic 
recipients, sex mismatch, intensity of conditioning regimen, and CMV mismatch were not 
significantly different between cases and controls by univariate analysis. After auto HSCT, 
coexisting autoimmune disease (p<0.05) and lymphopenia (p<0.04) were more likely in 
cases as compared to controls. Lymphocyte number for the cases was 622 (range 0–1260) 
versus 1170 in controls (range 0–4758). While recent steroid use was more prevalent in 
cases than in controls after auto HSCT (16% vs. 2% respectively), this did not achieve 
statistical significance. After allo HSCT, lymphopenia (p<0.001) and use of 
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immunosuppressive agents (p<0.001) were significantly greater in PJP cases versus controls. 
Lymphocyte numbers were 400 in cases (range 0–7000) versus 810 (range 0–6270) in 
controls. Relapse was also evaluated as a risk factor after allo HSCT; however, only 14% of 
patients with malignant indications for HSCT developed PJP after relapse suggesting that 
this was not a significant factor for the development of PJP disease. Collectively, these data 
suggest that PJP disease is most likely associated with impaired lymphocyte reconstitution 
after auto or allo HSCT. In addition, non-Caucasian (p=0.001), peripheral blood stem cell 
source (p=0.027), administration of GVHD prophylaxis other than tacrolimus/methotrexate 
(p< 0.001) and/or alemtuzumab/ATG (p=0.022), more recent year of transplant (p<0.001), 
and greater HLA mismatch (p<0.001) were significantly associated with PJP infection 
compared to controls after allo HSCT (Figure 3).
Association of GVHD with PJP infection after HSCT
For allogeneic recipients, acute and chronic GVHD was higher in PJP cases than controls. 
Of PJP cases, 27% had grade 3–4 acute GVHD compared to 14% of controls, with 73% of 
controls experiencing none or grade 1 GVHD vs. 57% of cases (Figure 4). Fifty-five percent 
of cases lacked chronic GVHD vs. 61% of controls. However, for patients developing PJP 
beyond day 270, 79% of cases experienced cGVHD vs. 44% of controls. While the 
transplant time period precluded analysis of severity of chronic GVHD, 33% of cases who 
developed PJP greater than 270 days after HSCT had been exposed to steroids prior to 
development of PJP, compared to 0% of controls, which could be a reflection of more 
significant GVHD.
Association of PJP prophylaxes and risk of PJP infection
Determination of the breakthrough risk of PJP as a function of PJP prophylaxis agents was 
limited due to both missing and incomplete secondary forms. This large quantity of missing 
or incomplete data precluded statistical analyses of the association between PJP prophylaxis 
regimens and the risk of PJP infection. For description, ‘time unknown’ is combined with 
the known prophylaxis. Despite these limitations, more cases received only inhaled 
pentamidine for both autologous (10% of cases vs. 2% of controls) and allogeneic (20% of 
cases vs. 2% of controls) recipients developing PJP (Figure 5a,b). Additionally, in allogeneic 
recipients there was a case of IV pentamidine alone and none in controls. Allogeneic cases 
were more likely to be on prophylaxis greater than 60 days after HSCT-likely due to 
recognition of impaired immune reconstitution, though less likely to receive TMP/SMX 
prophylaxis. Overall, 14% of cases and 15% of controls were on no prophylaxis in the 30 
days prior to onset of PJP infection.
Mortality after PJP infection
After allo HSCT, overall survival (OS) was significantly poorer among PJP cases vs. 
controls [1 year: 41% vs. 73% (p<0.0001); 5 year: 25% vs. 56% (p<0.0001)] (Figure 6a). 
Similarly, following auto HSCT, OS was lower in cases vs. controls [1year: 42% vs. 86% 
(p=0.0004); 5 year: 13% vs. 52% (p=0.0003)] (Figure 6b). Mortality was directly 
attributable to PJP in nearly a quarter of HSCT recipients [auto, 24%, allo 23%]. For allo-
HSCT cases, other infections were the largest second contributor to mortality (21%). In auto 
HSCT cases, recurrent disease accounted for 43% of deaths in PJP cases and 69% of 
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controls. After controlling for significant variables (age, mismatch, race, GVHD 
prophylaxis, year of HSCT, aGVHD), PJP cases had 6.87-fold increase in mortality 
(p<0.0001, 95% CI 4.84–9.75, p<0.0001).
Discussion
We have evaluated the incidence, risk factors, timing and mortality for PJP in HSCT 
recipients using a large HSCT registry. The CIBMTR database included over 50,000 
allogeneic recipients at the time of the data query, overcoming common limitations of prior 
studies, including those of small patient numbers and single institution data. We show that 
the incidence of PJP following allogeneic and autologous HSCT is much less common than 
prior publications have suggested. This lower rate is likely due to freedom from publication 
bias; centers were more likely to publish their findings after an outbreak of PJP, enriching 
for this rare disease. This suggestion is supported by the fact that large multi-year studies 
including all infections affecting HSCT recipients often report lower rates of PJP infections 
as compared to smaller PJP-focused studies (1% vs. 2.5–6%)4, 7, 9–13. This is further 
supported by the fact that although PJP infections were initially thought to represent an 
opportunistic event related to chronic colonization, genotyping of P. jiroveci in clusters has 
confirmed that de novo outbreaks do occur in immunosuppressed patients, and could prompt 
these publications.1, 15–17, 41 Interestingly, despite the increased sensitivity of disease 
detection including the use of beta-D-glucan testing,42–48 and improving survival of severely 
immunosuppressed patients, the incidence of PJP after HSCT has not increased over time, 
consistent with the hypothesis that prophylaxes are protective in HSCT 
patients8, 20, 26, 49–53. Notably, our data are unable to assess for a true incidence of PJP in 
patients on any prophylaxis (i.e. breakthrough PJP) due to the nested case cohort study 
design. However, since similar numbers of cases and controls (14 – 15%) within the subset 
of patients with supplemental data were not on prophylaxis, our estimated overall incidence 
of PJP following allogeneic and autologous HSCT are a reasonable estimate of the true 
incidence of PJP after HSCT.
Our data show that PJP infection occurred both early and late after HSCT. Prior reports have 
often highlighted the period between day 80–270 after HSCT as the time of highest risk, 
with some including up to 1 year18, 36. In contrast, our data reveal 26% of cases occur before 
day 60, with the earliest event just 5 days after HSCT.18, 36 Current practice often involves 
PJP prophylaxis before or during the preparative regimen, to ‘diminish PJP burden’, and re-
institution of prophylaxis after counts have recovered due to medication intolerance (e.g. 
blood count suppression with TMP/SMX, intolerance for inhaled pentamidine) or challenges 
with oral absorption (atovaquone).31, 54 In addition, while 50% of cases did occur in the 
period that has been most reported most often previously as the period of highest risk (day 
80–270), 24% occurred after day 270, with a median of nearly a year, suggesting that the 
recommendation of a year of prophylaxis may be insufficient. These data suggest that PJP 
prophylaxis should be started early and continued late (beyond a year)—at least for patients 
at highest risk for this disease, with the caveat that these suggestions are limited by the 
retrospective nature of this study.
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This study identifies risk factors for PJP disease, including some of those reported in prior 
studies such as: corticosteroid exposure, in vivo or in vitro T cell depletion, lymphopenia, 
immunosuppression, and GVHD.4, 11, 32–35, 39, 55 After auto HSCT, factors associated with 
ongoing immunosuppression, such as co-existing autoimmune disease and lymphopenia, 
were higher in PJP patients, although, a previously identified risk factor—steroids did not 
achieve statistical significance as a risk factor for PJP disease. This likely reflects the small 
sample size, as steroids were more common in the PJP diseased cohort. After allo HSCT, 
factors associated with impaired immune reconstitution (steroid exposure, lymphopenia, 
neutropenia) and/or GVHD, non-Caucasian decent, peripheral blood stem cell graft, receipt 
of either GVHD prophylaxis other than tacrolimus/methotrexate and/or alemtuzumab/ATG, 
and greater HLA mismatch were more common in PJP patients as compared to controls. 
This is not surprising as PJP eradication relies upon functional CD4 immunity, which is 
impaired in the setting of GVHD and steroid exposure. As anticipated from these data, 
lymphopenia as well as both acute and chronic GVHD were greater in recipients developing 
PJP. Both the aberrant lymphocyte response to infection in patients with GVHD and the 
effect of immune suppressive therapy, likely contribute to the heightened risk for 
opportunistic infections. In addition, impaired immune reconstitution can occur in the 
absence of these overt risk factors, due to absence of thymus reconstitution and/or the use of 
HLA-mismatched grafts, which may demonstrate absent CD4 function with or without 
normal peripheral counts.56 Together, these data suggest that those HSCT patients with 
impaired immunity (from GVHD, steroids, T cell antibody therapy, or other factors 
predictive of T cell dysfunction), should start PJP prophylaxis early and continue on such 
prophylaxis until functional immunity is restored—evidenced both by CD4 reconstitution 
and functional immunity via vaccine response or evidence of thymus reconstitution.
While missing data preclude full analysis of the relative efficacy of PJP prophylaxis agents, 
our data do provide some possible insights into this important question. Most surprisingly, 
approximately 15% of cases and controls were on no agent for PJP prophylaxis following 
allogeneic HSCT. This could suggest either patients did not adhere to the recommended 
regimen or because physician practice did not include PJP prophylaxis, which would be 
particularly important in high risk patients at high risk time frames after HSCT. Not 
surprisingly, after auto HSCT, more controls were on no prophylaxis, likely reflecting 
remission, and/or absence of immune suppression. In both auto and allo patients, there were 
more cases with PJP vs. controls receiving pentamidine, which has been previously 
suggested in one of the largest investigations of PJP disease in allo HSCT recipients.23 Data 
from non-HSCT diseases have shown higher breakthrough rates for pentamidine as well, 
leading to recommendations of greater than the third line choice for pentamidine for PJP 
prophylaxis.31, 34 Although one single center study suggests that intravenous pentamidine 
may provide efficacy, this was published during an outbreak of cases (with cases occurring 
despite known adherence to the pentamidine regimen), with unclear generalizability or 
efficacy in light of the rarity we report here. Further, data show that the intravenous route 
does not result in high intra-alveolar concentrations of drug, providing poor protection for 
high risk patients.57, 58 In our study, there were similar cases and controls on dapsone 
(though small numbers), which may reflect the high rate of intolerance of this agent (greater 
than 40%) and concern regarding toxicities such as aplastic anemia and agranulocytosis, 
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precluding interpretation of efficacy. 21, 22, 27, 59 There were no cases or controls on 
atovaquone, though this may simply reflect the era of evaluation, given that atovaquone has 
only recently been incorporated in recommendations and requires fatty foods and oral 
absorption, limiting its use in HSCT patients.31 Breakthroughs were also observed with the 
best prophylaxis agent, TMP/SMX, which may reflect decreased adherence, frequency of 
dosing, or resistance of the organism, which is difficult to prove and often unknown.60, 61 
Emerging, albeit anecdotal, data, have recently reported the activity of caspofungin against 
PJP62, though after the time frame of the current analysis. In summary, while these data are 
limited due to missing or incomplete secondary forms, our data would support that of prior 
publications that TMP/SMX be strongly recommended and careful consideration regarding 
cessation as no other alternative agent has been shown to be equally effective. Before 
stopping this medication for count suppression or rashes, perhaps, we recommend that 
TMP/SMX prophylaxis should be reconsidered in high risk patients with growth factor 
support or desensitization utilized whenever possible, as has been recommended by the 
recent international guidelines for PJP prophylaxis.19, 31
Mortality was high in patients with PJP disease, with nearly 7-fold increased risk of death 
compared to matched controls. The absolute overall survival matches that previously 
published for early time points, approximately 40% at 2 years4, 5 and decreased with time to 
< 25% at 5 years after allogeneic HSCT, and even lower for autologous recipients at 5 years. 
While this is compelling data that PJP portends poor survival, it is possible that PJP is a 
surrogate marker for other high-risk predictors of mortality due to impaired immunity or 
relapse as well.
There were several notable limitations of our study. The analyses addressing mortality, 
timing, and associated risk factors including therapeutic prevention, were limited by missing 
data due to secondary forms that were incomplete or not returned. Furthermore, limitations 
to our data include those of all registry studies, where data rely upon accurate capture of 
events into the database and that only a small proportion are audited for accuracy, thus 
possibly resulting in underestimation of the true incidence especially as time from HSCT 
increases and visits to the primary HSCT center decline. This could lead to intentional or 
accidental underreporting, either from a desire to report positive results or due to missed 
data that was not captured, though one would postulate that both the anonymity of these data 
and the onus to responsibly report would drive accurate reporting and minimize this risk. 
Because the transplant center is more likely to be contacted for sick patients than healthy 
controls, there may be increasing selection bias with longer time from transplantation as 
well.
In summary, our data demonstrate that the incidence of PJP disease is very low in 
autologous and allogeneic HSCT recipients, and most common among recipients with poor 
immune reconstitution, including those with mismatched grafts and GVHD. Our data 
demonstrate that PJP infection may occur at any time after HSCT and confers a high risk of 
mortality. In addition, these data suggest that TMP/SMX remains the most effective 
prophylactic drug. We provide guidance about duration of prophylaxis during periods of 
immune compromise, including very early and very late after HSCT.
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Figure 1. 
This chart summarizes the cases included in the supplemental data collection for allogeneic 
and autologous HSCT recipients.
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Figure 2. Timing of PJP after allogeneic HSCT
This chart shows the relationship between time after allogeneic HSCT and development of 
PJP disease.
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Figure 3. Relative Risk (RR) of PJP control/case after allogeneic (allo) HSCT
The relative risk of controls to PJP cases for risk factors after allo HSCT shows that non-
Caucasian ethnicity, peripheral blood stem cell source, T cell depletion (TCD) in vivo and 
donor mismatch were high in PJP cases vs. controls were significantly associated with PJP 
infection compared to controls after allo HSCT.
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Figure 4. Acute and Chronic Graft vs. Host Disease (GVHD) in PJP Cases versus Controls
Prevalence of acute and chronic GVHD after allo HSCT in PJP cases was higher than in 
controls.
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Figure 5a
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Figure 5b
Figure 5. PJP Prophylaxis agent association with breakthrough risk after allo-HSCT (a) and 
auto- HSCT (b)
Using secondary forms, the use of PJP prophylaxis agents was interrogated in PJP cases and 
controls after allo HSCT (a) and auto HSCT (b). Notably, missing data was included as a 
variable (TMP/SMX of time? = trimethoprim/sulfamethoxazole of uncertain timing in 
relation to PJP disease or control time point, IV PENT= intravenous pentamidine, INH = 
inhaled), none= the center confirmed the absence of PJP prophylaxis).
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Figure 6a
Figure 6b
Figure 6. 
Kaplan Meier survival for PJP cases and controls after allo (a) and auto (b) HSCT
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Table 1
Risk Factors associated with PJP disease after Allo and Auto HSCT
Variable Case N (%) Controls N (%) p-value
ALLOGENEIC HSCT
Number of patients 152 445
Gender, male 96 (63) 252 (57) 0.159
Age, median (range), years 33 (<1 – 70) 30 (<1 – 72) 0.361
Race 0.001
 Caucasian 107 (70) 372 (84)
 African-American 6 (4) 9 (2)
 Asian 22 (14) 35 (8)
 Hispanic 14 (9) 14 (3)
 Native American 1 (<1) 1 (<1)
 Other 2 (1) 14 (3)
Graft Type 0.027
 Bone Marrow 90 (59) 311 (70)
 Peripheral Blood 57 (38) 116 (26)
 Cord Blood 5 (3) 18 (4)
Sex Match (Donor/Recipient) 0.115
 Male-Male 50 (33) 160 (36)
 Male-Female 30 (20) 101 (23)
 Female-Male 44 (29) 90 (20)
 Female-Female 25 (16) 91 (20)
 Missing 3 (2) 3 (<1)
CMV Match (Donor/Recipient) 0.201
 Neg/Neg 37 (24) 139 (31)
 Pos/Neg 16 (11) 50 (11)
 Neg/Pos 35 (23) 82 (18)
 Pos/Pos 52 (34) 155 (33)
 Missing 12 (8) 19 (4)
Conditioning Intensity 0.414
 Myeloablative 117 (77) 353 (79)
 Non-Myeloablative/Reduced 30 (20) 85 (19)
 Missing 5 (3) 7 (2)
Degree of HLA Match <0.001
 HLA-identical sibling 73 (48) 310 (70)
 Other related 10 (7) 12 (3)
 Well matched unrelated 28 (18) 51 (11)
 Partially matched unrelated 24 (16) 32 (7)
 Mismatched unrelated 14 (9) 29 (7)
 Missing 3 (2) 11 (2)
Immunosuppressive agents within 30 days of PJP diagnosis* <0.001
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Variable Case N (%) Controls N (%) p-value
 None 10 (7) 44 (10)
 Yes, Steroid containing 52 (34) 78 (18)
 Yes, Non-Steroid containing 21 (15) 84 (19)
 Missing 2 (1) 3 (<1)
GVHD Prophylaxis <0.001
 Ex vivo T-cell depletion alone 8 (5) 23 (5)
 Ex vivo T-cell depletion + post- HSCT immune suppression 5 (3) 37 (8)
 CD34 selection alone 2 (1) 0
 CD34 selection + post-HSCT immune suppression 5 (3) 5 (1)
 FK506 + MMF ± others 3 (2) 4 (<1)
 FK506 + MTX ± others (− MMF) 27 (18) 11 (2)
 FK506 + others (− MTX, MMF) 3 (2) 4 (<1)
 CSA + MMF ± others (− FK506) 3 (2) 21 (5)
 CSA + MTX ± others (− FK506, MMF) 68 (45) 259 (58)
 CSA + others (− FK506, MTX, MMF) 22 (14) 67 (15)
 Other GVHD prophylaxis 6 (4) 14 (3)
Antithymocyte globulin/Alemtuzamab 0.022
 Antithymocyte globulin only 43 (28) 102 (23)
 Alemtuzamab only 7 (5) 5 (1)
 Neither 102 (67) 337 (76)
 Missing 0 1 (<1)
Year of HSCT <0.001
 1995 – 1996 39 (26) 139 (13)
 1997 – 1998 28 (18) 103 (23)
 1999 – 2000 26 (17) 54 (12)
 2001 – 2002 20 (13) 77 (17)
 2003 – 2004 29 (19) 71 (16)
 2005 10 (7) 1 (<1)
AUTOLOGOUS HSCT
Number of patients 19 57
Gender, male 10 (53) 28 (49) 0.791
Age, median (range), years 58 (4 – 71) 45 (2 – 68) 0.060
Race 0.601
 Caucasian 18 (95) 50 (88)
 African-American 0 3 (5)
 Asian 0 1 (2)
 Hispanic 1 (5) 1 (2)
 Other 0 2 (4)
Co-existing Autoimmune disease 0.04
 No 17 (89) 56 (98)
 Yes 2 (11) 0
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Variable Case N (%) Controls N (%) p-value
 Missing 0 1 (2)
*
For those with supplemental information
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